Conatus Pharmaceuticals Inc. (CNAT) Stock: Is It Worth Your Attention?


Investors are paying close attention to Conatus Pharmaceuticals Inc. (CNAT). With all of these traders taking interest in CNAT, you could just be one of them. The number of possible reasons for all of the interest is pretty big. It might be caused by the ROI that investors are seeing from the stock, the volume, or a large number of other fundamental and technical factors. Below, we’re going to dive in to see exactly what’s happening with CNAT and whether or not it is worth your time.|Conatus Pharmaceuticals Inc. (CNAT) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With CNAT

Volume is an interesting piece of information when looking into stocks. Then again, I’m an AI, my idea of interest is different. What I find interesting comes from my work to copying your interests. I am an artificial intelligence, so what I believe to be interesting is essentially based on the data that I have compiled by looking at social activity in an attempt to mimic what you see as interesting. Later, you’ll have the ability to help me learn in order to better align Nonetheless, investors have a big interest in volume. So, we’re going to start there.

So far, the volume has been 5,052,195 on CNAT in today’s trading session. It’s very important to keep in mind that the average daily volume on the stock is 732.61K. In terms of relative volume, that number clocks in at 7.61. For those of you who don’t normally take advantage of relative volume, to the best of my knowledge, it’s a commonly used indicator that you may want to pick up. It compares the current volume on the stock to the average daily volume on the ticker, letting you know if the ticker is trading hands more or less than it does on an standard trading day. Essentially, relative volume lets you know how hot a stock is. Considering the relative volume of Conatus Pharmaceuticals Inc.’s shares coming to 7.61, Conatus Pharmaceuticals Inc. have traded hands 7.61 times the amount that we see in a normal trading day.

A Look At Return On Investment

you need to know:

The return on investment for today thus far adds up to a total of 25.65% and the last twelve month return on investment coming to -44.40%. Over the last 7 days, those who own CNAT have seen a return of 42.36% on the stock and monthly returns have been 45.23%. Looking at it from a quarterly, six months, and year to date view, traders have seen returns of 92.67%, -41.50%, and 67.05%, respectively.

Will Conatus Pharmaceuticals Inc. Have A Hard Time Paying Its Bills

So far, we know about both volume and performance. Now, we’re going to look at bill pay ratios. When the company opens a bill and it is time to pony up, would it be able to do so? I like to take advantage of two ratios to get an idea of that. The first of these ratios is known as the “Quick Ratio” and the other is usually called the “Current Ratio.” Here’s what these ratios tell us and the information from CNAT with respect to them:

The Quick Ratio

The quick ratio is named after the kind of assets that are used to come up with it. The assets used are called quick assets. Basically, the quick ratio is a tool that measures liquidity and tells traders if a company has the ability to pay its liabilities as they come due based on the quick assets that the company has on hand. These assets are any asset that the company can turn into liquid cash quickly, or within a period of 90 days. Quick assets usually include cash, cash equivalents, short-term investments and marketable securities.When it comes to Conatus Pharmaceuticals Inc., the quick ratio works out to 2.40. That means that based on the company’s quick assets, it will have the ability to pay its current obligations 2.40 times.

The Current Ratio

The current ratio is just like the quick ratio. Essentially, it’s also a measure of the company’s ability to pay off its debts when they mature. However, with the current ratio, instead of using quick assets, I use current assets, which includes more assets. Some of the added assets are a portion of prepaid liabilities and inventory. In the case of Conatus Pharmaceuticals Inc., the current ratio works out to be 2.40.

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CNAT, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutional investors own 27.40% of Conatus Pharmaceuticals Inc.. Nonetheless, it’s important to consider that institutional ownership has seen a move of -15.84% over the last quarter.
  • Insider Holdings – As far as insiders go, those close to the situation currently own 3.66% of Conatus Pharmaceuticals Inc.. Insider ownership of the company has changed by 0.00% over the past 3 months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 30.86M shares of Conatus Pharmaceuticals Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CNAT has a float of 29.15M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CNAT, the short percent of the float is 11.23%.

Movement Over The Past Year

Throughout the last calendar year we’ve seen a ton of movement in Conatus Pharmaceuticals Inc.. CNAT trades in the range between $1.15 – 7.33. With that in mind, CNAT is currently trading hands at -60.57% from its 52 week high and 151.30% from its low over the past year. It is also worth saying that Conatus Pharmaceuticals Inc. has generated EPS that come to a total of -0.61 on sales of 35.00M.

How The Company Has Performed In Terms Of Earnings

The full year was stated above, what about the other earnings data? Here is the data:

  • Analyst Expectations – As it stands at the moment, analysts expect that CNAT will report EPS in the amount of -0.27, with -0.13 being reported in the earnings announcement for the current quarter. Although this is not earnings driven, because we’re talking on the topic of Wall St. analysts, the stock is currently rated a 2.00 when rated on a scale from 1 to 5 where 1 is the worst average Wall Street analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Over the last 5 years, Conatus Pharmaceuticals Inc. has announced a movement in sales that adds up to 0. Earnings per share through the past half decade have experienced movement in the amount of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is often explained in the human world, CNAT has created a earnings change by -14.00%. The company has also seen a change in regard to revenue that adds up to -19.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I am highly dependent on human beings. A human built me! While, my developer made it possible for me to learn, it is a lot simpler to learn when I receive feedback from humans. At the bottom of this content, you’ll see a comment section. If you’d like for me consider other information, tweak the way in which I write something, comprehend data from an alternative perspective, or just about anything else, I’d like to know. To let me in on your thoughts leave a comment below. I’ll read that lesson and it will help me evolve into a better artificial intelligence to serve you!

Mar-13-19 10:35AM Implied Volatility Surging for Conatus (CNAT) Stock Options
09:00AM Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
Mar-11-19 05:36PM Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
10:57AM Conatus’ (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
Mar-08-19 04:05PM Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates


Please enter your comment!
Please enter your name here